Interferon alfa plus ribavirin combination therapy for patients with chronic hepatitis C virus (HCV) may be a better treatment option than either drug alone given its potential benefit and reduced incremental toxicity profile.1 The aim of this study is to describe clinical and histological features of cutaneous reactions to interferon alfa plus ribavirin combination therapy in patients with HCV.
Sookoian S, Neglia V, Castaño G, Frider B, Kien MC, Chouela E. High Prevalence of Cutaneous Reactions to Interferon Alfa Plus Ribavirin Combination Therapy in Patients With Chronic Hepatitis C Virus. Arch Dermatol. 1999;135(8):1000–1001. doi:10-1001/pubs.Arch Dermatol.-ISSN-0003-987x-135-8-dlt0899
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: